

Synthesis of Carboxymethyl GLA-60 Ether Derivatives Containing an Olefin in Their Chains and Their LPS-Antagonistic Activities

Tsuyoshi Nakamura, Yukiko Watanabe, Masao Shiozaki,^{*,#} Saori Kanai,[†] and Shin-ichi Kurakata[†]

Exploratory Chemistry Research Laboratories, Sankyo Co. Ltd., Hiromachi 1-2-58, Shinagawa-ku, Tokyo 140-8710

[†]Biological Research Laboratories, Sankyo Co. Ltd., Hiromachi 1-2-58, Shinagawa-ku, Tokyo 140-8710

(Received August 1, 2002)

Anomeric carboxymethyl GLA-60 olefine derivatives having ether chains instead of ester chains in their side chains were synthesized and their biological activities toward both human U937 cells and mouse PEC-macrophage cells were measured. The species-specific behavior of these compounds in humans (LPS-antagonistic) and mice (very weak LPS-antagonistic, but almost inactive) found this time was different from that in humans (LPS-antagonistic) and mice (endotoxic) found in the biosynthetic precursor of lipid A, such as lipid IVa. However, this fact also shows, interestingly enough, that a difference exists in the molecular recognition between human and mouse LPS receptors.

Since Shiba and Kusumoto's total synthesis of lipid A (Fig. 1),¹ a toxic component of endotoxin (lipopolysaccharide; LPS) existing in the outer surface membrane of Gram-negative bacteria, the study of endotoxin has developed extensively.² Endotoxin and its related compounds have been investigated as anticancer drugs² by stimulating the immune system.³ Also, in recent years, lipid A-related compounds have been studied as LPS-antagonists, which may have potential as immunosuppressants in autoimmune diseases and septicemia by deactivating the LPS-induced immune system.² In fact, a non-toxic natural lipid A-related compound isolated from *Rhodobacter sphaeroides*⁴ showed a LPS-antagonistic activity, and the Eisai group has developed a related compound, E5564,

as a highly potent anti-septicemia drug.⁵

During our investigation of the biological activities of compounds related to GLA-60,⁶ which is a nonreducing distal sub-unit of a lipid A analogue, we found that some anomeric α -carboxymethyl GLA-60 analogues had LPS-antagonistic activity toward human U937 cells.⁷ It was also found that LPS-antagonist for human macrophages obtained from *Rhodobacter sphaeroides* having a unique structural feature, that is, containing an olefine and a ketone in its long chains of fatty acids, does not show LPS-agonistic activity toward mouse macrophages.⁸ Furthermore, it was revealed by the Eisai group that many lipid A-related compounds having an olefinic double bond in their molecules behave as LPS-antagonists to-




Fig. 1. Structures of Lipid A, E-5564 and GLA-60.

Present address: Chemistry Department, Chemtech Labo., Inc., Hiromachi 1-2-58, Shinagawa-ku, Tokyo 140-8710

ward both human and murine macrophages.⁸ Therefore, we were interested in the LPS-antagonistic activity of the anomeric carboxymethyl GLA-60 ether derivatives containing an olefin in their molecules. We synthesized compounds **16**, **17**, **24**, **25**, **37**, and **38** to measure the LPS-antagonistic activity toward human U937 cells and mouse PEC-macrophage cells. We would like to describe the synthesis of the compounds and their LPS-antagonistic activity in this paper.

Results and Discussion


Firstly, we tried the synthesis of C-6 hydroxy compound **16** and C-6 methoxy compound **17** possessing four chains in their molecules. The compounds (*R*)-3-(alkenyl)tetradecanoic acid **4**, carboxylic acid **5**⁹ and mesylate **6** for side chains were synthesized from aldehyde **1**, which was obtained by a modification of reported methods¹⁰ (Scheme 1). The acetal **2** of (*R*)-tetradecane-1,3-diol¹¹ and aldehyde **1**, obtained by a treatment with camphorsulfonic acid (CSA) as a catalyst, were converted to primary alcohol **3** by hydridodiisobutylaluminum (DIBAL) reduction. A Swern oxidation of alcohol **3** with oxalyl chloride and dimethyl sulfoxide (DMSO) yielded an aldehyde, which was further oxidized to carboxylic acid **4** by sodium chlorite in the presence of 2-methyl-2-butene and sodium dihydrogenphosphate in *t*-butyl alcohol.⁹ The same treatment of aldehyde **1** also gave carboxylic acid **5**.⁹ On the other hand, the mesylation of **3** by methanesulfonyl chloride (MsCl) using *N,N*-diisopropylethylamine (*i*-Pr₂NEt) as a base gave mesylate **6**.

The starting allyl 2-deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-4,6-*O*-isopropylidene-2-trifluoroacetamido- α -D-glucopyranoside **7**¹² was converted to anomeric 2-hydroxyethyl compound **8** by OsO₄–NaIO₄ cleavage of the allylic double bond and successive reduction of the resulting aldehyde with NaBH₄ according to the reported procedure.¹³ Saponification of trifluoroacetamide group of **8** with methanolic NaOH gave amine **9**. A treatment of **9** with carboxylic acid **4** and dicyclohexylcarbodiimide (DCC) gave amide **10**. Dess-Martin periodinane oxidation¹⁴ of alcohol **10**, successive treatments of the resulting aldehyde with sodium chlorite in the presence of 2-methyl-


2-butene and sodium dihydrogenphosphate in *t*-BuOH,¹³ and finally esterification of the resulting carboxylic acid with allyl bromide and Et₃N gave allyl ester **11**. Acetonide of **11** was cleaved with CSA in MeOH, and successive silylation of the C-6 primary alcohol of the resulting diol with *t*-butyldimethylsilyl chloride (TBDMSCl) and imidazole as a base yielded silyl ether **12**. The treatment of the C-4 secondary alcohol of **12** with diallyl diisopropylphosphoramidite and 1*H*-tetrazole, and a successive treatment of the resulting phosphite with 40% H₂O₂ afforded phosphate **13**. The treatment of **13** with 5% aq. H₂SO₄ in acetone for desilylation gave alcohol **14**, which was treated with trimethyloxonium tetrafluoroborate (Me₃OB⁺F₄) in the presence of 2,6-di-*t*-butyl-4-methylpyridine (DTBMP) to give a C-6 methoxy compound **15**. The allyl protecting groups of **14** and **15** were cleaved by reactions with PPh₃, Et₃N–HCOOH, and [Pd(PPh₃)₄] in tetrahydrofuran (THF) at 50 °C for 4 hours to give deprotected compounds **16** and **17**, respectively¹⁵ (Scheme 2).

Secondly, we tried to synthesize the C-6 hydroxy compound **24** and the C-6 methoxy compound **25** possessing three chains in their molecules. The reaction of **9** with (*Z*)-tetradec-7-enoic acid using DCC as a condensing reagent gave amide **18**, which was converted to allyl ester **19** according to the same procedure from **10** to **11**. The same procedure of **19** from **11** to **16** or **17** via compounds **12**, **13** and **14** or compounds **12**, **13**, **14** and **15** gave **24** or **25** through compounds **20**, **21**, and **22** or compounds **20**, **21**, **22**, and **23**, respectively (Scheme 3).

Thirdly, we tried to synthesize C-6 hydroxy compound **37** and C-6 methoxy compound **38** possessing three chains in their molecules. Compound **26**¹⁶ was converted to alcohol **27** according to the same procedure from **7** to **8**. Selective protection of the primary alcohol of **27** with 4-methoxybenzyl chloride in DMF using NaH as a base gave ether **28**. A treatment of the secondary alcohol **28** in DMF with mesylate **6** using NaH as a base gave ether **29**. The trifluoroacetyl protecting group of amide **29** was cleaved by 1 M aq NaOH in EtOH, giving free amine, which was treated with 2,2-difluorotetradecanoic acid using DCC as a condensing reagent and 4-dimethylaminopyridine (DMAP) to afford amide **30**. Deprotection of the 4-



Scheme 1. Reagents and conditions: a) (*R*)-tetradecane-1,3-diol, CSA, benzene, azeotropic distillation, 100%; b) DIBAL, toluene, 50 °C, 10 h, 81%; c) (1) (COCl)₂, DMSO, CH₂Cl₂, –78 °C, 1 h, then Et₃N, 0 °C, 1 h; (2) NaClO₂, 2-methyl-2-butene, NaH₂PO₄, *t*-BuOH, rt, 3 h, two steps 88% (**4**) and 96% (**5**); d) MeSO₂Cl, *i*-Pr₂NEt, CH₂Cl₂, rt, 4 h, 100%.




Scheme 2. Reagents and conditions: Allyl = $\text{CH}_2\text{CH}=\text{CH}_2$; TBDMS = *t*-butyldimethylsilyl; a) (1) OsO_4 , NaIO_4 , acetone– H_2O , rt, 1.5 h, (2) NaBH_4 , MeOH, 0°C , 30 min, 2 steps 47%; b) NaOH, MeOH– H_2O , 50°C , 5 h, 93%; c) **4**, DCC, CH_2Cl_2 , 0°C , 4 h, 85%; d) (1) Dess–Martin periodinane, 0°C , 3 h, (2) NaClO_2 , NaH_2PO_4 , 2-methyl-2-butene, *t*-BuOH– H_2O , rt, 2 h, (3) $\text{CH}_2=\text{CHCH}_2\text{Br}$, Et_3N , DMF, 50°C , 4 h, three steps, 46%; e) CSA, MeOH, rt, 2 h, then TBDMS-Cl, imidazole, DMF, rt, 2.5 h, 87%; f) *i*-Pr₂NP ($\text{OCH}_2\text{CH}=\text{CH}_2$)₂, 1*H*-tetrazole, THF, rt, 1.5 h, then aq H_2O_2 , rt, 1.5 h, 81%; g) aq 5% H_2SO_4 , acetone, rt, 4.5 h, 80%; h) Me_3OBF_4 , DTBMP, CH_2Cl_2 , rt, 54%; i) $[\text{Pd}(\text{PPh}_3)_4]$, PPh_3 , Et_3N – HCOOH , THF, 50°C , 4 h, 78% (**16**) and 85% (**17**).

methoxybenzyl ether of **30** with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and H_2O was performed to yield alcohol **31**, which was converted to allyl ester **32** according to the same procedure from **10** to **11**. The acetonide of **32** was deprotected by a treatment with 80% aq. AcOH at 60°C to afford diol **33**. The same procedure of **33** from **11** to **13** gave diallyl phosphate **34**. A treatment of **34** with 3 M aq HCl in THF afforded alcohol **35**, which was further converted to C-6-methyl ether **36** by Me_3OBF_4 treatment. The deprotection of allyl groups from **35** and **36** with $[\text{Pd}(\text{PPh}_3)_4]$, PPh_3 , Et_3N , and HCOOH in THF yielded C-4 phosphono carboxylic acids **37** and **38**, respectively (Scheme 4).

Biological activity: The inhibitory activity of the six synthesized compounds (**16**, **17**, **24**, **25**, **37**, and **38**) on LPS-induced TNF α production was investigated in vitro using both

human monoblastic U937 cells and mouse PEC-macrophage cells. The IC_{50} values (nM) of these six compounds (**16**, **17**, **24**, **25**, **37**, and **38**) toward human monoblastic U937 cells were 20.0, 13.0, 8.6, 37.0, 7.1, and 15.0, respectively. The activity toward human monoblastic U937 cells of these six monosaccharide compounds having a double bond in their three or four long chains were disappointingly much less active than that of our previously reported lipid A-type pyran carboxylic acids ($\text{IC}_{50} = 0.6\text{--}6.4$ nM).¹² In conclusion, it might be true that even though the compounds have a double bond in the long chains, if they are monosaccharides the LPS-antagonistic activity toward human monoblastic U937 cells would not exceed that of the lipid A-type disaccharides.

Additionally, the IC_{50} values (nM) of these six compounds (**16**, **17**, **24**, **25**, **37**, and **38**) toward mouse PEC-macrophage



Scheme 3. Reagents and conditions: Allyl = $\text{CH}_2\text{CH}=\text{CH}_2$; TBDMS = *t*-butyldimethylsilyl; a) **5**, DCC, CH_2Cl_2 , 0°C , 2.5 h, 84%; b) (1) Dess-Martin periodinane, CH_2Cl_2 , 0°C , 3.5 h, 0°C , 3 h, (2) NaClO_2 , NaH_2PO_4 , 2-methyl-2-butene, *t*-BuOH– H_2O , rt, 1 h, (3) $\text{CH}_2=\text{CHCH}_2\text{Br}$, Et_3N , DMF, rt, 11 h, three steps 51%; c) (1) CSA, MeOH–THF, rt, 1 h; (2) TBDMS–Cl, imidazole, DMF, rt, 1 h, two steps, 99%; d) *i*-Pr₂NP ($\text{OCH}_2\text{CH}=\text{CH}_2$)₂, 1*H*-tetrazole, THF, rt, 3 h, and then 40% aq H_2O_2 , 1 h, 85%; e) 5% aq H_2SO_4 , acetone, rt, 5 h, 76%; f) Me_3OBF_4 , DTBMP, CH_2Cl_2 , rt, 4 h, 54%; g) $[\text{Pd}(\text{PPh}_3)_4]$, PPh_3 , Et_3N – HCOOH , THF, 50°C , 7 h, 78% (**24**) and 85% (**25**).

cells were >10000, >10000, 1686, 1907, 6141, and 8259, respectively. Among these compounds, compounds **16** and **17** having four chains in their molecules are completely lacking any activity. The other four compounds (**24**, **25**, **37**, and **38**) have three chains in their molecules. Also, the activity of compounds **37** and **38**, containing two fluorines, is much weaker than compounds **24** and **25**. The difference of C-6 OH and OMe does not much affect the activity. In conclusion, as compared with the activity toward human monoblastic U937 cells, the activity of these six compounds toward mouse PEC-macrophage cells is almost inactive.


The species-specific behavior of these compounds in humans (LPS-antagonistic) and mice (very weak LPS-antagonistic, but almost inactive) found this time was different from that in humans (LPS-antagonistic) and mice (endotoxic) found in the biosynthetic precursor of lipid A, such as lipid IVa.¹⁷ However, this fact also shows, interestingly enough, that a difference exists in the molecular recognition between human and mouse LPS receptors.

Experimental

¹H NMR spectra were recorded with JEOL-GSX 400 and JNM-ECT 500 spectrometers using TMS as an internal standard. IR absorption spectra were measured with an IR A-2 spectrophotometer, and mass spectra were obtained with a JMS-700 mass spectrometer. Separation of compounds by column chromatogra-

phy was performed with silica gel 60 (230–400 mesh ASTM) under a slightly elevated pressure (1.1–1.8 atm) for easy elution. Commercially available anhydrous THF and dichloromethane were used for the reactions. DMF and pyridine were dried by storage over 4 Å molecular sieves.

(Z)-7-Tetradecenal (1). (i) To a solution of 1-octyne (45.1 mL, 307 mmol) in THF (450 mL) was slowly added a 1.5 M solution of *n*-BuLi in hexane (204 mL, 307 mmol) at -45°C . After stirring for 10 min at 0°C , this reaction mixture was cooled to -45°C and hexamethylphosphoric triamide (HMPA) (53.4 mL, 307 mmol) and 6-bromohexan-1-ol tetrahydropyranyl ether (67.8 g, 256 mmol) were added. After stirring for 22 h at room temperature, to the resulting mixture was slowly added sat. aq NH_4Cl (50 mL), and the mixture was poured into water. After extraction with ether, the organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was dissolved in MeOH (400 mL) containing CSA (2.2 g, 10 mmol). After stirring for 24 h at room temperature, to the reaction mixture was added Et_3N (50 mL), and the mixture was evaporated in vacuo to give a crude product, which was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford 65.4 g of a crude product, which was purified by distillation under reduced pressure (bp 130 – 138°C at 4 mmHg) to give tetradec-7-yn-1-ol (47.7 g, 88%) as a colorless oil; bp 130 – 138°C (at 4 mmHg). IR (neat) 3341 , 2932 , 2859 , 1464 cm^{-1} . ¹H NMR (500 MHz, CDCl_3) δ



Scheme 4. Reagents and conditions: Allyl = $\text{CH}_2\text{CH}=\text{CH}_2$; PMB = 4-methoxybenzyl; TBDMS = *t*-butyldimethylsilyl; a) (1) OsO_4 , NaIO_4 , acetone– H_2O –*t*-BuOH, rt, 1.5 h, (2) NaBH_4 , MeOH, 0 °C, 30 min; 2 steps 70%; b) PMBCl , NaH, DMF, 0 °C, 15 min, 87%; c) **6**, NaH, DMF, rt, 3 h, 85%; d) (1) aq 1 M NaOH, EtOH, 60 °C, 4 h, (2) $\text{HOOC}(\text{CF}_2)_{12}\text{H}_{25}$, DCC, DMAP, CH_2Cl_2 , rt, 1 h, two steps, 96%; e) DDQ, CH_2Cl_2 , H_2O , rt, 2 h, 84%; f) (1) Dess–Martin periodinane, 0 °C, 3 h, (2) NaClO_2 , NaH_2PO_4 , 2-methyl-2-butene, *t*-BuOH– H_2O , rt, 2 h, (3) $\text{CH}_2=\text{CHCH}_2\text{Br}$, Et_3N , DMF, 50 °C, 4 h, three steps, 71%; g) aq 80% AcOH, 60 °C, 3 h, 93%; h) (1) TBDMS–Cl, DMAP, CH_2Cl_2 , rt, 3 h, (2) *i*-Pr₂NP(OCH₂CH=CH₂)₂, 1*H*-tetrazole, THF, rt, 1.5 h, then aq 30% H_2O_2 , 0 °C, 1 h, 84%; i) 3 M aq HCl, THF, rt, 5 h, 91%; j) Me_3OBF_4 , DTBMP, CH_2Cl_2 , rt, 4 h, 77%; k) $[\text{Pd}(\text{PPh}_3)_4]$, PPh_3 , Et_3N –HCOOH, THF, 50 °C, 7 h, 85% (**37**) and 92% (**38**), respectively.

0.89 (3H, t, $J = 7.8$ Hz), 1.23–1.53 (16H, m), 1.58 (2H, quintet, $J = 7.8$ Hz), 2.12–2.18 (4H, m), 3.65 (2H, t, $J = 5.9$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{14}\text{H}_{27}\text{O}$ ($\text{M} + \text{H}$)⁺: 211.2062. Found: 211.2053.

(ii) To a solution of tetradec-7-yn-1-ol (10.6 g, 50 mmol) in hexane (200 mL) was added Lindlar's catalyst (1.0 g). After stirring for 9 h at room temperature under a hydrogen atmosphere, the reaction mixture was filtered using Celite. The filtrate was concentrated in vacuo to afford a crude product of (*Z*)-tetradec-7-en-1-ol. To a solution of $(\text{COCl})_2$ (8.7 mL, 100 mmol) in CH_2Cl_2 (200 mL) was slowly added DMSO (14.2 mL, 200 mmol) at –78 °C. After stirring for 10 min, to this reaction mixture was added a solution of the previously obtained (*Z*)-tetradec-7-en-1-ol (10.7 g, 50 mmol) in CH_2Cl_2 (200 mL). After stirring for 1 h, the reaction mixture was slowly added Et_3N (55 mL, 400 mmol) and stirred for 1 h at 0 °C. The mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column

chromatography. Elution with hexane gave **1** (8.7 g, 83%) as a colorless oil. IR (neat) 1728 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (3H, t, $J = 6.6$ Hz), 1.23–1.40 (12H, m), 1.64 (2H, quintet, $J = 7.3$ Hz), 1.95–2.07 (4H, m), 2.42 (2H, dt, $J = 1.5$ Hz, 6.6 Hz), 5.29–5.40 (2H, m), 9.77 (1H, d, $J = 1.5$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{14}\text{H}_{26}\text{O}$ (M)⁺: 210.1984. Found: 210.1980.

(**2S,4R**)-4-Undecyl-2-[(*Z*)-tridec-6-enyl]-1,3-dioxane (**2**). To a solution of **1** (10.1 g, 48 mmol) and (*R*)-tetradecan-1,3-diol (12.2 g, 53 mmol) in benzene (100 mL) was added CSA (0.50 g, 2.2 mmol). After refluxing for 2 h at 50 °C at 70 mmHg to remove H_2O azeotropically, the reaction mixture was cooled to room temperature and sat. aq NaHCO_3 (10 mL) was added. The resulting mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc:hexane (0:10, and then 1:9) afforded **2** (21.4 g, quantitatively) as a colorless oil. $[\alpha]_D -1.1$ (c 0.8, CHCl_3). IR

(neat) 2925, 2855, 1465 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (3H, t, $J = 6.8$ Hz), 0.89 (3H, t, $J = 6.8$ Hz), 1.23–1.46 (34H, m), 1.54–1.68 (4H, m), 1.97–2.05 (4H, m), 3.52–3.59 (1H, m), 3.71 (1H, dt, $J = 11.7$ Hz, 2.9 Hz), 4.09 (1H, dd, $J = 4.9$ Hz, 11.7 Hz), 4.49 (1H, t, $J = 4.9$ Hz), 5.30–5.40 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{28}\text{H}_{54}\text{O}_2$ (M^+): 422.4124. Found: 422.4116.

(R)-3-[(Z)-Tetradec-7-enyloxy]tetradecan-1-ol (3). To a solution of **2** (21.4 g, 48 mmol) in toluene was added a 1.0 M solution of DIBAL in toluene. After stirring 10 h at 50 $^\circ\text{C}$, the reaction mixture was cooled to room temperature and sat. aq NH_4Cl (20 mL), sat. aq Rochelle salt (30 mL) and H_2O (100 mL) were slowly added. The resulting mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9) afforded **3** (16.5 g, 81%) as a colorless oil. $[\alpha]_D -19.7$ (c 1.0, CHCl_3). IR (neat) 3375, 1466 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (6H, t, $J = 6.8$ Hz), 1.23–1.38 (32H, m), 1.42–1.50 (1H, m), 1.51–1.62 (3H, m), 1.65–1.73 (1H, m), 1.74–1.81 (1H, m), 1.98–2.05 (4H, m), 2.79 (1H, t, $J = 6.9$ Hz), 3.39 (1H, dt, $J = 7.8$ Hz, 8.8 Hz), 3.45–3.55 (2H, m), 3.70–3.84 (2H, m), 5.30–5.40 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{28}\text{H}_{57}\text{O}_2$ ($\text{M} + \text{H}^+$): 425.4359. Found: 425.4356.

(R)-3-[(Z)-Tetradec-7-enyloxy]tetradecanoic acid (4). To a solution of oxalyl chloride (0.83 mL, 9.6 mmol) in CH_2Cl_2 (10 mL) was slowly added DMSO (1.4 mL, 19 mmol) at -78 $^\circ\text{C}$. After stirring for 10 min, to the reaction mixture was added a solution of **3** (2.0 g, 4.8 mmol) in CH_2Cl_2 . After stirring for 1 h, to the reaction mixture was slowly added Et_3N (5.3 mL, 38 mmol) and the reaction mixture was stirred for 1 h at 0 $^\circ\text{C}$. The mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product. To a solution of this crude product in t -BuOH (4.5 mL) and H_2O (1.5 mL) were added 2-methyl-2-butene (2.6 mL, 24 mmol), NaH_2PO_4 (1.1 g, 7.2 mmol), and NaClO_2 (1.3 g, 14 mmol). After stirring for 3 h at room temperature, the reaction mixture was poured into 1 M aq HCl and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9) afforded **4** (1.9 g, 88%) as a colorless oil. $[\alpha]_D -5.6$ (c 1.1, CHCl_3). IR (neat) 1712 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (6H, t, $J = 6.8$ Hz), 1.22–1.40 (32H, m), 1.46–1.65 (4H, m), 1.94–2.06 (4H, m), 2.54 (2H, d, $J = 6.8$ Hz), 3.46–3.55 (2H, m), 3.69 (1H, quintet, $J = 5.9$ Hz), 5.30–5.40 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{28}\text{H}_{55}\text{O}_3$ ($\text{M} + \text{H}^+$): 439.4151. Found: 439.4131.

(Z)-Tetradec-7-enoic acid (5). To a solution of aldehyde **1** (1.6 g, 7.6 mmol) in t -BuOH (7.5 mL) and H_2O (2.5 mL) were added 2-methyl-2-butene (4.0 mL, 38 mmol), NaH_2PO_4 (1.8 g, 11.4 mmol), and NaClO_2 (2.6 g, 22.8 mmol). After stirring for 3 h at room temperature, the reaction mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9, and then 1:4) afforded **5** (1.6 g, 96%) as a colorless oil. IR (neat) 1710 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (3H, t, $J = 6.8$ Hz), 1.22–1.40 (12H, m), 1.60–1.69 (2H, m),

1.86–2.07 (4H, m), 2.35 (2H, t, $J = 7.8$ Hz), 5.32–5.39 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{14}\text{H}_{26}\text{O}_2$ (M^+): 226.1933. Found: 226.1923.

1-Methylsulfonyloxy-3-[(R)-[(Z)-tetradec-7-enyloxy]]tetradecane (6). To a solution of **3** (6.6 g, 15.5 mmol) in CH_2Cl_2 (20 mL) was added N,N -diisopropylethylamine (4.0 mL, 23.3 mmol) and MsCl (1.4 mL, 18.6 mmol). After stirring for 4 h at room temperature, the reaction mixture was added sat. aq NaHCO_3 (5 mL). The resulting mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9) afforded **6** (7.8 g, quantitatively) as a colorless oil. $[\alpha]_D -18.7$ (c 0.2, CHCl_3). IR (neat) 1466, 1416, 1359, 1179 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (6H, t, $J = 7.8$ Hz), 1.22–1.39 (32H, m), 1.40–1.48 (1H, m), 1.50–1.58 (3H, m), 1.79–1.87 (1H, m), 1.98–2.05 (4H, m), 3.00 (3H, s), 3.35–3.43 (2H, m), 3.47 (1H, dt, $J = 6.8$ Hz, 8.8 Hz), 4.29–4.40 (2H, m), 5.30–5.40 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{29}\text{H}_{59}\text{O}_4\text{S}$ ($\text{M} + \text{H}^+$): 503.4134. Found: 503.4143.

2-Hydroxyethyl 2-Deoxy-3-O-[(R)-3-(dodecyloxy)tetradecyl]-4,6-O-isopropylidene-2-trifluoroacetamido- α -D-glucopyranoside (8). To a solution of **7** (6.6 g, 9.1 mmol) in acetone (15 mL) and H_2O (5 mL) were added NaIO_4 (7.8 g, 36.4 mmol) and a 2.5 wt% solution of OsO_4 in t -BuOH (0.5 mL). After stirring 1.5 h at room temperature, the reaction mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford 7.0 g of a crude product. To a solution of this crude product in MeOH (10 mL) was slowly added NaBH_4 (0.41 g, 10.9 mmol) at 0 $^\circ\text{C}$. After stirring for 0.5 h, the reaction mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford 6.4 g of a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9, and then 3:7) afforded **8** (3.2 g, 47%) as a colorless oil. $[\alpha]_D +24.4$ (c 1.0, CHCl_3). IR (neat) 3435, 3309, 3084, 1720, 1561, 1466, 1380, 1371 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (6H, t, $J = 7.8$ Hz), 1.22–1.36 (36H, m), 1.41 (3H, s), 1.49–1.55 (5H, m, involving 3H, s, at δ 1.51), 1.61–1.70 (4H, m), 3.30–3.40 (3H, m), 3.52–3.59 (2H, m), 3.60–3.66 (1H, m), 3.66–3.90 (8H, m), 4.15 (1H, dt, $J = 9.8$ Hz, 3.9 Hz), 4.93 (1H, d, $J = 3.9$ Hz), 6.90 (1H, d, $J = 7.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{39}\text{H}_{73}\text{F}_3\text{NO}_8$ ($\text{M} + \text{H}^+$): 740.5288. Found: 740.5269.

2-Hydroxyethyl 2-Amino-2-deoxy-3-O-[(R)-3-(dodecyl-oxy)tetradecyl]-4,6-O-isopropylidene- α -D-glucopyranoside (9). To a solution of **8** (3.2 g, 4.3 mmol) in MeOH (15 mL) and H_2O (2 mL) was added NaOH (0.34 g, 8.6 mmol). After stirring for 5 h at 50 $^\circ\text{C}$, the reaction mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to yield a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (3:7) afforded **9** (2.6 g, 93%) as a colorless oil. $[\alpha]_D +40.8$ (c 1.2, CHCl_3). IR (neat) 3371, 3295, 1587, 1466, 1380, 1369, 1267 cm^{-1} . $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.88 (6H, t, $J = 6.8$ Hz), 1.23–1.38 (35H, m), 1.40 (3H, s), 1.42–1.57 (9H, m, involving a singlet at δ 1.49), 1.68–1.77 (4H, m), 2.77 (1H, dd, $J = 3.9$ Hz, 9.8 Hz), 3.29 (1H, t, $J = 8.8$ Hz), 3.33–3.45 (3H, m), 3.56 (1H, t, $J = 9.8$ Hz), 3.62–3.69 (2H, m), 3.69–3.74 (2H, m), 3.74–

3.86 (4H, m), 3.93 (1H, td, $J = 5.9$ Hz, 9.8 Hz), 4.92 (1H, d, $J = 3.9$ Hz). HRFABMS m/z (positive-ion); Calcd for $C_{37}H_{74}NO_7$ ($M + H$)⁺: 644.5465. Found: 644.5466.

2-Hydroxyethyl 2-Deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-4,6-*O*-isopropylidene-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (10**).** To a solution of **9** (0.92 g, 1.4 mmol) and (*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanoic acid **4** (0.75 g, 1.7 mmol) in CH_2Cl_2 (3 mL) was added DCC (0.43 g, 2.1 mmol) at 0 °C. After stirring for 2.5 h, to the reaction mixture was added hexane (5 mL), and the mixture was filtered. The filtrate was concentrated in vacuo to give a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:4) afforded **10** (1.3 g, 84%) as a colorless oil. $[\alpha]_D +23.0$ (c 0.9, $CHCl_3$). IR (neat) 3317, 1646, 1545, 1466 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$) δ 0.88 (12H, t, $J = 6.8$ Hz), 1.22–1.66 (84H, m, involving 3H two singlets at δ 1.41 and δ 1.50), 1.67–1.75 (1H, m), 1.95–2.06 (4H, m), 2.34 (1H, dd, $J = 7.8$ Hz, 15.6 Hz), 2.41 (1H, dd, $J = 3.9$ Hz, 15.6 Hz), 3.31–3.39 (3H, m, involving a triplet at δ 3.37, $J = 6.8$ Hz), 3.42–3.49 (3H, m), 3.54–3.61 (2H, m), 3.66–3.86 (8H, m), 4.14–4.20 (1H, m), 4.88 (1H, d, $J = 3.9$ Hz), 5.30–5.40 (2H, m), 6.72 (1H, d, $J = 8.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $C_{65}H_{126}NO_9$ ($M + H$)⁺: 1064.9433. Found: 1064.9438.

(Allyloxycarbonyl)methyl 2-Deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-4,6-*O*-isopropylidene-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (11**).** To a solution of **10** (1.2 g, 1.1 mmol) in CH_2Cl_2 (20 mL) was added Dess-Martin periodinane (1.2 g, 2.9 mmol) at 0 °C. After stirring for 3.5 h, to the reaction mixture were added sat. aq $NaHCO_3$ (1 mL) and sat. aq $Na_2S_2O_3$ (1 mL). The resulting mixture was poured into water and extracted with ether. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo to afford a crude product. To a solution of this crude product in *t*-BuOH (3 mL) and H_2O (1 mL) were added 2-methyl-2-butene (0.5 mL, 4.6 mmol), NaH_2PO_4 (0.27 g, 1.7 mmol) and $NaClO_2$ (0.40 g, 3.5 mmol). After stirring for 1 h at room temperature, the reaction mixture was poured into water, and extracted with ether. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo to afford a crude product. Furthermore, to a solution of this crude product in DMF (2 mL) were added Et_3N (0.64 mL, 4.6 mmol) and allyl bromide (0.30 mL, 3.5 mmol). After stirring for 11 h at room temperature, sat. aq $NaHCO_3$ (1 mL) was added to the reaction mixture, which was poured into water and extracted with ether. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9, and then 1:4) gave **11** (0.66 g, 51%) as a colorless oil. $[\alpha]_D +30.4$ (c 0.3, $CHCl_3$). IR (neat) 3320, 1759, 1658, 1536, 1466, 1372 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$) δ 0.88 (12H, t, $J = 6.8$ Hz), 1.21–1.60 (82H, m, involving 3H two singlets at δ 1.40 and 1.49, respectively), 1.68–1.75 (2H, m), 1.97–2.06 (4H, m), 2.39 (1H, dd, $J = 6.8$ Hz, 14.7 Hz), 2.44 (1H, dd, $J = 3.9$ Hz, 14.7 Hz), 3.30–3.51 (6H, m), 3.58 (1H, dt, $J = 9.8$ Hz, 6.8 Hz), 3.63–3.85 (6H, m), 4.16 (1H, d, $J = 3.9$ Hz), 5.27 (1H, d, $J = 8.8$ Hz), 5.30–5.40 (3H, m), 5.90 (1H, ddt, $J = 10.7$ Hz, 17.5 Hz, 5.9 Hz), 6.82 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $C_{68}H_{128}NO_{10}$ ($M + H$)⁺: 1118.9538. Found: 1118.9557.

(Allyloxycarbonyl)methyl 6-*O*-(*t*-Butyldimethylsilyl)-2-de-

oxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (12**).** To a solution of **11** (0.59 g, 0.53 mmol) in MeOH (3 mL) and THF (1 mL) was added CSA (45 mg, 0.19 mmol). After stirring for 1 h at room temperature, the reaction mixture was added Et_3N (1 mL) and evaporated in vacuo to give a crude diol. To a solution of this diol in DMF (1 mL) were added imidazole (72 mg, 1.1 mmol) and TBDMSCl (88 mg, 0.58 mmol). After stirring for 1 h at room temperature, sat. aq $NaHCO_3$ (1 mL) was added to the reaction mixture, which was poured into water and extracted with ether. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9, and then 1:4) afforded **12** (0.62 g, 99%) as a colorless oil. $[\alpha]_D +26.3$ (c 0.6, $CHCl_3$). IR (neat) 3353, 1758, 1655, 1535, 1465 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$) δ 0.08 (6H, s), 0.88 (12H, t, $J = 6.8$ Hz), 0.90 (9H, s), 1.22–1.60 (76H, m), 1.71 (2H, q, $J = 5.9$ Hz), 1.96–2.05 (4H, m), 2.37–2.45 (2H, m), 3.34–3.51 (6H, m), 3.56–3.71 (4H, m), 3.74–3.80 (1H, m), 3.82 (1H, dd, $J = 3.9$ Hz, 10.7 Hz), 3.85 (1H, dd, $J = 2.9$ Hz, 10.7 Hz), 4.18 (2H, s), 4.21 (1H, dt, $J = 3.9$ Hz, 9.8 Hz), 4.63 (2H, d, $J = 5.9$ Hz), 4.83 (1H, d, $J = 2.9$ Hz), 5.26 (1H, d, $J = 10.7$ Hz), 5.30–5.40 (3H, m), 5.90 (1H, ddt, $J = 17.5$, 10.7, 4.9 Hz), 6.81 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $C_{71}H_{138}NO_{10}Si$ ($M + H$)⁺: 1193.0090. Found: 1193.0084.

(Allyloxycarbonyl)methyl 6-*O*-(*t*-Butyldimethylsilyl)-2-deoxy-4-*O*-bis(allyloxy)phosphoryl-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (13**).** To a solution of **12** (0.62 g, 0.52 mmol) in THF (2 mL) were added diallyl diisopropylphosphoramidite (0.21 mL, 0.78 mmol) and 1*H*-tetrazole (73 mg, 1.0 mmol). After stirring for 3 h at room temperature, to the reaction mixture was added 40% aq H_2O_2 (0.3 mL). After further stirring for 1 h, sat. aq $Na_2S_2O_3$ (0.5 mL) was slowly added to the reaction mixture, which was poured into water and extracted with ether. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9) afforded **13** (0.60 g, 85%) as a colorless oil. $[\alpha]_D +28.5$ (c 0.7, $CHCl_3$). IR (neat) 3320, 1759, 1677, 1535, 1464 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$) δ 0.05 (6H, s), 0.88 (12H, t, $J = 6.8$ Hz), 0.89 (9H, s), 1.21–1.58 (74H, m), 1.66–1.80 (2H, m), 1.98–2.04 (4H, m), 2.39 (2H, d, $J = 5.9$ Hz), 3.24–3.36 (3H, m), 3.45 (2H, t, $J = 6.8$ Hz), 3.60–3.80 (7H, m), 3.95 (1H, d, $J = 9.8$ Hz), 4.15 (1H, d, $J = 16.6$ Hz), 4.19 (1H, d, $J = 16.6$ Hz), 4.23–4.31 (2H, m), 4.53–4.59 (4H, m), 4.63 (2H, d, $J = 5.9$ Hz), 4.84 (1H, d, $J = 3.9$ Hz), 5.28–5.40 (8H, m), 5.85–5.98 (3H, m), 6.84 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $C_{77}H_{147}NO_{13}PSi$ ($M + H$)⁺: 1353.0379. Found: 1353.0371.

(Allyloxycarbonyl)methyl 4-*O*-Bis(allyloxy)phosphoryl-2-deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (14**).** To a solution of **13** (0.60 g, 0.44 mmol) in acetone (1 mL) was added 5% aq H_2SO_4 (0.2 mL). After stirring for 5 h at room temperature, the reaction mixture was quenched with sat. aq $NaHCO_3$ (0.2 mL) and poured into water. After extraction with ether, the organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (3:7, and then 1:1) afforded **14** (0.42

g, 76%) as a colorless oil. $[\alpha]_D +19.9$ (c 1.0, CHCl_3). IR (neat) 3319, 1757, 1655, 1541, 1465 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (12H, t, $J = 6.8$ Hz), 1.22–1.78 (78H, m), 1.96–2.06 (4H, m), 2.39 (2H, d, $J = 5.9$ Hz), 3.23–3.37 (3H, m), 3.45 (2H, t, $J = 6.8$ Hz), 3.56–3.64 (2H, m), 3.66–3.74 (2H, m), 3.74–3.83 (2H, m), 3.92–3.98 (2H, m), 4.15 (1H, d, $J = 16.6$ Hz), 4.20 (1H, d, $J = 16.6$ Hz), 4.29 (1H, td, $J = 3.9$ Hz, 10.7 Hz), 4.40 (1H, q, $J = 9.8$ Hz), 4.56 (2H, t, $J = 6.8$ Hz), 4.62–4.67 (4H, m), 4.85 (1H, d, $J = 3.9$ Hz), 5.24–5.41 (8H, m), 5.86–5.99 (3H, m), 6.81 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{71}\text{H}_{133}\text{NO}_{13}\text{P}$ ($M + \text{H}^+$): 1238.9515. Found: 1238.9519.

(Allyloxycarbonyl)methyl 4-*O*-bis(allyloxy)phosphoryl-2-deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (15). To a solution of **14** (120 mg, 0.094 mmol) and 2,6-di-*t*-butyl-4-methylpyridine (280 mg, 1.3 mmol) in CH_2Cl_2 (0.5 mL) was added Me_3OBF_4 (130 mg, 0.94 mmol). After stirring for 4 h at room temperature, the reaction mixture was quenched with sat. aq NaHCO_3 (0.5 mL) and poured into water. After extraction with ether, the organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (3:7) afforded **15** (63 mg, 54%) as a colorless oil. $[\alpha]_D +27.0$ (c 0.3, CHCl_3). IR (neat) 3321, 1757, 1675, 1537, 1465 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (12H, t, $J = 6.8$ Hz), 1.22–1.58 (78H, m), 1.66–1.80 (4H, m), 1.96–2.06 (4H, m), 2.38 (2H, d, $J = 5.9$ Hz), 3.24–3.30 (1H, m), 3.31–3.36 (2H, m), 3.39 (3H, s), 3.44 (2H, t, $J = 6.8$ Hz), 3.60–3.78 (6H, m), 3.89 (1H, dt, $J = 3.9$, 10.7 Hz), 4.20 (3H, s), 4.30 (1H, dt, $J = 3.9$, 10.7 Hz), 4.37 (1H, q, $J = 9.8$ Hz), 4.54–4.62 (m, 4H), 4.63 (2H, d, $J = 5.9$ Hz), 4.87 (1H, d, $J = 3.9$ Hz), 5.23–5.40 (8H, m), 5.85–5.99 (3H, m), 6.83 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{72}\text{H}_{135}\text{NO}_{13}\text{P}$ ($M + \text{H}^+$): 1252.9671. Found: 1252.9677.

Carboxymethyl 2-Deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-4-*O*-phosphono-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (16). To a solution of **14** (94 mg, 0.076 mmol) and PPh_3 (10 mg, 0.038 mmol) in THF (0.3 mL) were added Et_3N (53 μL , 0.38 mmol), HCO_2H (29 μL , 0.76 mmol) and $[\text{Pd}(\text{PPh}_3)_4]$ (2 mg, 0.002 mmol). After stirring for 7 h at 50 $^\circ\text{C}$, the reaction mixture was evaporated in vacuo to give a crude product, which was purified by DEAE-cellulose column chromatography. The column was eluted with CHCl_3 –MeOH–0.1 M aq $\text{CH}_3\text{COONH}_4$ (2:1:0, and then 2:3:1). The product containing fractions were concentrated in vacuo to give a crude product, which was dissolved in CHCl_3 (4 mL), MeOH (8 mL) and 0.1 M aq HCl (3 mL). To this solution was added another volume of CHCl_3 (4 mL) and 0.1 M aq HCl (4 mL) to separate the solution into two phases. The lower CHCl_3 phase was collected and concentrated to give **16** (66 mg, 78%) as a white powder. $[\alpha]_D +25.6$ (c 0.5, CHCl_3). IR (CHCl_3) 3634, 3340, 1754, 1663, 1521, 1466 cm^{-1} . ^1H NMR (500 MHz, CD_3OD) δ 0.90 (9H, t, $J = 6.8$ Hz), 1.25–1.57 (76H, m), 1.69–1.81 (2H, m), 1.98–2.08 (4H, m), 2.35 (1H, dd, $J = 5.9$ Hz, 14.7 Hz), 2.49 (1H, dd, $J = 14.7$ Hz, 6.8 Hz), 3.34–3.48 (4H, m), 3.50–3.56 (1H, m), 3.66 (2H, t, $J = 9.8$ Hz), 3.70–3.77 (2H, m), 3.77–3.83 (2H, m), 3.89 (1H, q, $J = 8.8$ Hz), 4.08 (1H, dd, $J = 3.9$ Hz, 10.7 Hz), 4.10–4.17 (2H, m, involving a doublet at δ 4.13, $J = 16.6$ Hz), 4.25 (1H, d, $J = 16.6$ Hz), 4.81 (1H, d, $J = 2.9$ Hz), 5.31–5.40 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{62}\text{H}_{120}\text{NO}_{13}\text{PNa}$ ($M + \text{Na}^+$): 1140.8395. Found:

1140.8383.

Carboxymethyl 2-Deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-6-*O*-methyl-4-*O*-phosphono-2-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecanamido]- α -D-glucopyranoside (17). Compound **15** (63 mg, 0.050 mmol) was treated as described in the formation of **16** from **14** to give **17** (48 mg, 85%) as a white powder. $[\alpha]_D +33.1$ (c 0.60, CHCl_3). IR (CHCl_3) 3691, 3607, 3341, 1736, 1671, 1603, 1525, 1467 cm^{-1} . ^1H NMR (500 MHz, CD_3OD) δ 0.90 (12H, t, $J = 6.8$ Hz), 1.24–1.58 (78H, m), 1.68–1.82 (2H, m), 2.00–2.07 (4H, m), 2.34 (1H, dd, $J = 4.9$ Hz, 14.7 Hz), 2.49 (1H, dd, $J = 14.7$ Hz, 6.8 Hz), 3.36–3.42 (5H, m, involving a singlet at δ 3.38), 3.44–3.48 (2H, m), 3.52 (1H, dt, $J = 5.9$ Hz, 11.7 Hz), 3.59 (1H, dd, $J = 5.9$ Hz, 10.7 Hz), 3.63–3.70 (2H, m), 3.70–3.77 (2H, m), 3.84–3.90 (2H, m), 4.08 (1H, dd, $J = 2.9$ Hz, 10.7 Hz), 4.12 (1H, d, $J = 16.6$ Hz), 4.14 (1H, q, $J = 9.8$ Hz), 4.24 (1H, d, $J = 16.6$ Hz), 4.79 (1H, d, $J = 2.9$ Hz), 5.31–5.40 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{63}\text{H}_{122}\text{NO}_{13}\text{PNa}$ ($M + \text{Na}^+$): 1154.8552. Found: 1154.8561.

2-Hydroxyethyl 2-Deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-4,6-*O*-isopropylidene-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (18). To a solution of **9** (0.93 g, 1.4 mmol) in CH_2Cl_2 (3 mL) and (*Z*)-tetradec-7-enoic acid **5** (0.39 g, 1.7 mmol) was added DCC (0.45 g, 2.2 mmol) at 0 $^\circ\text{C}$. After stirring for 4 h, the reaction mixture was diluted with hexane (5 mL) and filtered. The filtrate was concentrated in vacuo to give a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:4, and then 2:3) afforded **18** (1.0 g, 85%) as a colorless oil. $[\alpha]_D +29.1$ (c 2.0, CHCl_3). IR (neat) 3306, 1644, 1544, 1465, 1379 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (9H, t, $J = 7.8$ Hz), 1.22–1.57 (58H, m, involving 3H, two singlets at δ 1.40 and δ 1.50, respectively), 1.60–1.73 (4H, m), 1.94–2.06 (4H, m), 2.19 (2H, t, $J = 7.8$ Hz), 3.34–3.43 (3H, m, involving a triplet at δ 3.36, $J = 5.9$ Hz), 3.44–3.49 (1H, m), 3.52–3.63 (2H, m), 3.65–3.87 (8H, m), 4.09–4.15 (1H, m), 4.97 (1H, d, $J = 2.9$ Hz), 5.29–5.39 (2H, m), 6.05 (1H, d, $J = 8.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{51}\text{H}_{97}\text{NO}_8$ ($M + \text{H}^+$): 851.7214. Found: 852.7286.

(Allyloxycarbonyl)methyl 2-Deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-4,6-*O*-isopropylidene-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (19). Compound **18** (0.41 g, 0.48 mmol) was treated as described in the formation of **11** from **10** to afford **19** (0.18 g, 46%) as a colorless oil. $[\alpha]_D +32.0$ (c 0.7, CHCl_3). IR (neat) 3306, 1759, 1650, 1544, 1465, 1379 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (9H, t, $J = 6.8$ Hz), 1.21–1.46 (53H, m, involving a singlet at δ 1.40), 1.47–1.56 (5H, m, involving a singlet at δ 1.49), 1.58–1.72 (4H, m), 1.95–2.06 (4H, m), 2.22 (2H, dt, $J = 6.8$ Hz, 1.9 Hz), 3.32–3.39 (3H, m), 3.44–3.50 (1H, m), 3.54–3.60 (1H, m), 3.67–3.76 (3H, m), 3.76–3.84 (2H, m), 4.16 (1H, d, $J = 17.6$ Hz), 4.22 (1H, d, $J = 17.6$ Hz), 4.23 (1H, dt, $J = 10.7$ Hz, 3.9 Hz), 4.65 (2H, d, $J = 5.9$ Hz), 4.79 (1H, d, $J = 3.9$ Hz), 5.27 (1H, d, $J = 8.8$ Hz), 5.30–5.40 (3H, m), 5.91 (1H, ddt, $J = 10.7$ Hz, 17.5 Hz, 5.9 Hz), 6.09 (1H, d, $J = 8.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{54}\text{H}_{100}\text{NO}_9$ ($M + \text{H}^+$): 906.7398. Found: 906.7397.

(Allyloxycarbonyl)methyl 6-*O*-(*t*-Butyldimethylsilyl)-2-deoxy-3-*O*-[(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (20). Compound **19** (0.59 g, 0.65 mmol) was treated as described in the formation of **12** from **11** to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9, and then 1:4) afforded **20** (0.56 g, 87%) as a colorless oil. $[\alpha]_D +30.9$ (c 0.5, CHCl_3). IR (neat) 3313, 1756, 1650, 1543, 1465 cm^{-1} .

^1H NMR (500 MHz, CDCl_3) δ 0.08 (6H, s), 0.88 (9H, t, $J = 6.8$ Hz), 0.90 (9H, s), 1.22–1.44 (48H, m), 1.49–1.75 (8H, m), 1.94–2.05 (4H, m), 2.20–2.27 (2H, m), 3.37 (2H, t, $J = 6.8$ Hz), 3.39–3.44 (1H, m), 3.48 (1H, dd, $J = 8.8, 10.7$ Hz), 3.60–3.78 (4H, m), 3.81–3.88 (2H, m), 4.17 (1H, d, $J = 16.6$ Hz), 4.20–4.25 (2H, m, involving 1H, d, $J = 16.6$ Hz, at δ 4.23), 4.64 (2H, d, $J = 5.9$ Hz), 4.78 (1H, d, $J = 3.9$ Hz), 5.27 (1H, d, $J = 10.7$ Hz), 5.30–5.40 (3H, m), 5.90 (1H, ddt, $J = 17.5, 10.7, 4.9$ Hz), 6.15 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{57}\text{H}_{110}\text{NO}_9\text{Si}$ ($\text{M} + \text{H}$) $^+$: 980.7950. Found: 980.7963.

(Allyloxy carbonyl)methyl 4-*O*-bis(allyloxy)phosphoryl-6-*O*-(*t*-butyldimethylsilyl)-2-deoxy-3-*O*-(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (21). Compound **20** (0.55 g, 0.56 mmol) was treated as described in the formation of **13** from **12** to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (1:9, and then 1:4) afforded **21** (0.52 g, 81%) as a colorless oil. $[\alpha]_D^{25} +31.5$ (c 1.0, CHCl_3). IR (neat) 3308, 1757, 1660, 1541, 1464 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.05 (6H, s), 0.88 (9H, t, $J = 6.8$ Hz), 0.89 (9H, s), 1.23–1.76 (56H, m), 1.95–2.05 (4H, m), 2.23 (2H, t, $J = 7.8$ Hz), 3.26–3.32 (1H, m), 3.33 (2H, t, $J = 6.8$ Hz), 3.59–3.66 (2H, m), 3.73–3.81 (3H, m), 3.94 (1H, d, $J = 9.8$ Hz), 4.16 (1H, d, $J = 17.6$ Hz), 4.21–4.30 (2H, m, involving 1H, d, $J = 17.6$ Hz, at δ 4.24), 4.53–4.59 (4H, m), 4.64 (2H, d, $J = 5.9$ Hz), 4.79 (1H, d, $J = 3.9$ Hz), 5.20–5.39 (8H, m), 5.86–5.99 (3H, m), 6.15 (1H, d, $J = 9.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{63}\text{H}_{119}\text{NO}_{12}\text{PSi}$ ($\text{M} + \text{H}$) $^+$: 1140.8239. Found: 1140.8242.

(Allyloxy carbonyl)methyl 4-*O*-bis(allyloxy)phosphoryl-2-deoxy-3-*O*-(*R*)-3-(dodecyloxy)tetradecyl]-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (22). Compound **21** (0.52 g, 0.46 mmol) was treated as described in the formation of **14** from **13** to afford a crude product, which was purified by silica-gel column chromatography. Elution with EtOAc–hexane (3:7, and then 1:1) afforded **22** (0.38 g, 80%) as a gum. $[\alpha]_D^{25} +34.7$ (c 0.6, CHCl_3). IR (neat) 3312, 1757, 1654, 1543, 1465 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (9H, t, $J = 6.8$ Hz), 1.22–1.55 (52H, m), 1.62–1.73 (4H, m), 1.97–2.05 (4H, m), 2.23 (2H, t, $J = 6.8$ Hz), 3.27–3.38 (3H, m), 3.59 (2H, t, $J = 9.8$ Hz), 3.67–3.76 (2H, m), 3.82 (1H, q, $J = 8.8$ Hz), 4.40 (1H, q, $J = 9.8$ Hz), 4.56 (2H, dd, $J = 4.9, 7.8$ Hz), 4.61–4.67 (4H, m), 4.82 (1H, d, $J = 3.9$ Hz), 5.24–5.41 (8H, m), 5.86–5.98 (3H, m), 6.18 (1H, d, $J = 8.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{57}\text{H}_{105}\text{NO}_{12}\text{P}$ ($\text{M} + \text{H}$) $^+$: 1026.7374. Found: 1026.7362.

(Allyloxy carbonyl)methyl 4-*O*-bis(allyloxy)phosphoryl-2-deoxy-3-*O*-(*R*)-3-(dodecyloxy)tetradecyl]-6-*O*-methyl-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (23). Compound **22** (120 mg, 0.12 mmol) was treated as described in the formation of **15** from **14** to afford **23** (67 mg, 55%) as a colorless oil. $[\alpha]_D^{25} +34.4$ (c 0.77, CHCl_3). IR (neat) 3310, 1756, 1653, 1542, 1465 cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ 0.88 (9H, t, $J = 6.8$ Hz), 1.22–1.54 (52H, m), 1.62–1.76 (4H, m), 1.97–2.05 (4H, m), 2.23 (2H, t, $J = 7.8$ Hz), 3.26–3.32 (1H, m), 3.33 (2H, t, $J = 5.9$ Hz), 3.39 (3H, s), 3.63 (2H, t, $J = 8.8$ Hz), 3.66 (2H, d, $J = 3.9$ Hz), 3.74–3.81 (1H, m), 3.88 (1H, dt, $J = 3.9, 10.7$ Hz), 4.36 (1H, q, $J = 9.8$ Hz), 4.54–4.62 (4H, m), 4.67 (2H, d, $J = 5.9$ Hz), 4.82 (1H, d, $J = 3.9$ Hz), 5.23–5.41 (8H, m), 5.86–5.99 (3H, m), 6.15 (1H, d, $J = 8.8$ Hz). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{58}\text{H}_{107}\text{NO}_{12}\text{P}$ ($\text{M} + \text{H}$) $^+$: 1040.7530. Found: 1040.7537.

Carboxymethyl 2-Deoxy-3-*O*-(*R*)-3-(dodecyloxy)tetradecyl]-4-*O*-phosphono-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyr-

anoside (24). Compound **22** (74 mg, 0.072 mmol) was treated as described in the formation of **16** from **14** to give **24** (26 mg, 40%) as a white powder. $[\alpha]_D^{25} +30.3$ (c 0.3, CH_3OH). IR (CHCl_3) 3691, 3607, 1734, 1654, 1603, 1466 cm^{-1} . ^1H NMR (500 MHz, CD_3OD) δ 0.90 (9H, t, $J = 6.8$ Hz), 1.23–1.48 (51H, m), 1.50–1.57 (2H, m), 1.60–1.69 (2H, m), 1.70–1.77 (2H, m), 2.00–2.10 (4H, m), 2.25 (2H, dt, $J = 7.8$ Hz, 2.0 Hz), 3.35–3.42 (2H, m), 3.43–3.48 (1H, m), 3.62–3.69 (2H, m), 3.70–3.76 (1H, m), 3.76–3.84 (2H, m), 3.87–3.93 (1H, m), 4.07 (1H, dd, $J = 2.9, 9.8$ Hz), 4.10–4.18 (2H, m, containing 1H, d, $J = 16.6$ Hz, at δ 4.14), 4.25 (1H, d, $J = 16.6$ Hz), 4.80 (1H, d, $J = 2.9$ Hz), 5.31–5.42 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{48}\text{H}_{92}\text{NO}_{12}\text{PNa}$ ($\text{M} + \text{Na}$) $^+$: 928.6255. Found: 928.6250.

Carboxymethyl 2-Deoxy-3-*O*-(*R*)-3-(dodecyloxy)tetradecyl]-6-*O*-methyl-4-*O*-phosphono-2-[(*Z*)-7-tetradecenamido]- α -D-glucopyranoside (25). Compound **23** (65 mg, 0.062 mmol) was treated as described in the formation of **16** from **14** to give **25** (49 mg, 86%) as a white powder. $[\alpha]_D^{25} +34.5$ (c 0.3, CH_3OH). IR (CHCl_3) 3690, 3438, 1752, 1676, 1604, 1511, 1466 cm^{-1} . ^1H NMR (500 MHz, CD_3OD) δ 0.90 (9H, t, $J = 6.8$ Hz), 1.24–1.50 (52H, m), 1.50–1.57 (2H, m), 1.60–1.68 (2H, m), 1.70–1.80 (2H, m), 2.00–2.08 (4H, m), 2.25 (2H, dt, $J = 8.8, 2.0$ Hz), 3.35–3.43 (5H, m, containing 3H, s, at δ 3.38), 3.45 (1H, dt, $J = 5.9, 9.8$ Hz), 3.59 (1H, dd, $J = 5.9, 10.7$ Hz), 3.63–3.69 (2H, m), 3.74 (1H, d, $J = 8.8$ Hz), 3.83–3.90 (2H, m), 4.07 (1H, dd, $J = 3.9, 10.7$ Hz), 4.11–4.17 (2H, m, containing 1H, d, $J = 16.6$ Hz, at δ 4.13), 4.25 (1H, d, $J = 16.6$ Hz), 4.78 (1H, d, $J = 2.9$ Hz), 5.31–5.41 (2H, m). HRFABMS m/z (positive-ion); Calcd for $\text{C}_{49}\text{H}_{94}\text{NO}_{12}\text{PNa}$ ($\text{M} + \text{Na}$) $^+$: 942.6411. Found: 942.6399.

2-Hydroxyethyl 2-Deoxy-4,6-*O*-isopropylidene-2-trifluoroacetamido- α -D-glucopyranoside (27). Compound **26** (355 mg, 1.00 mmol) was treated as described in the formation of **8** from **7** to give **27** (252 mg, 2 steps 70%) as a white solid. IR (KBr) 3435, 3084, 2995, 2941, 2923, 1719 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 1.44 (3H, s), 1.53 (3H, s), 1.84 (1H, brs, OH), 3.30 (1H, brs, OH), 3.56–3.90 (9H, m), 4.19 (1H, dt, $J = 3.7, 9.5$ Hz), 4.90 (1H, d, $J = 3.7$ Hz), 7.46 (1H, d, $J = 8.1$ Hz, NH). FABMS (positive-ion); m/z 382 ($\text{M} + \text{Na}$) $^+$, 360 ($\text{M} + \text{H}$) $^+$. FABMS (negative-ion) m/z 686 ($\text{M} - \text{H}$) $^-$. HRFABMS m/z (positive-ion); Calcd for $\text{C}_{13}\text{H}_{21}\text{F}_3\text{NO}_7$: 360.1270. Found: 360.1274. Anal. Calcd for $\text{C}_{13}\text{H}_{20}\text{F}_3\text{NO}_7$ (359.3): C, 43.46; H, 5.61; N, 3.90; F, 15.86%. Found: C, 43.38; H, 5.53; N, 3.85; F, 15.88%.

2-(4-Methoxybenzyloxy)ethyl 2-Deoxy-4,6-*O*-isopropylidene-2-trifluoroacetamido- α -D-glucopyranoside (28). To a solution of **27** (1.80 g, 5.01 mmol) in DMF (20 mL) was gradually added NaH (60% oil dispersion, 245 mg, 6.13 mmol) at 0 °C with stirring. After 15 min, 4-methoxybenzyl chloride (0.73 mL, 5.24 mmol) was added to this solution, which was stirred for 5 h at room temperature. The reaction mixture was quenched with cold water, extracted with EtOAc, washed with water and brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to give a mixture that was chromatographed on a silica-gel column. Elution with hexane–EtOAc (2:3) gave **28** (2.08 g, 87%). IR (CHCl_3) 3600, 3426, 2938, 2917, 2882, 1731, 1612 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 1.43 (3H, s), 1.51 (3H, s), 3.63–3.85 (8H, m, containing 3H, s, at δ 3.81), 4.18 (1H, td, $J = 3.7, 5.9$ Hz), 4.46, 4.50 (2H, AB-q, $J = 11.7$ Hz), 4.86 (1H, d, $J = 3.7$ Hz), 6.89 (2H, d, $J = 8.8$ Hz), 7.25 (2H, d, $J = 8.8$ Hz). FABMS (positive-ion); m/z 502 ($\text{M} + \text{Na}$) $^+$, 480 ($\text{M} + \text{H}$) $^+$. HRFABMS m/z (positive-ion); Calcd for $\text{C}_{21}\text{H}_{28}\text{F}_3\text{NO}_8\text{Na}$: 502.1665. Found: 502.1677.

2-(4-Methoxybenzyloxy)ethyl 2-Deoxy-4,6-O-isopropylidene-3-O-[(R)-3-[(Z)-tetradec-7-enyloxy]tetradecyl]-2-trifluoroacetamido- α -D-glucopyranoside (29). To a solution of **28** (1.35 g, 2.82 mmol) in DMF (10 mL) was gradually added NaH (60% oil dispersion, 285 mg, 7.13 mmol) at 0 °C with stirring. After 15 min, **6** (1.43 g, 2.84 mmol) was added to this solution, which was stirred for 3 h at room temperature. The reaction mixture was quenched with water, extracted with EtOAc, washed with water and brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo to give a mixture that was chromatographed on a silica-gel column. Elution with hexane–EtOAc (3:1) gave **29** (2.12 g, 85%). IR (CHCl₃) 3428, 2929, 2856, 1733, 1613 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (6H, t, J = 6.6–7.3 Hz), 1.26–1.32 (36H, m), 1.41 (3H, s), 1.50 (3H, s), 1.61–1.71 (2H, m), 1.97–2.02 (4H, m), 3.27–3.41 (3H, m), 3.49–3.86 (14H, m, containing 3H, s, at δ 3.81), 4.17 (1H, dt, J = 3.7, 9.5 Hz), 4.46, 4.49 (2H, AB-q, J = 11.7 Hz), 4.86 (1H, d, J = 3.7 Hz), 5.31–5.38 (2H, m), 6.83 (1H, d, J = 9.5 Hz, NH), 6.89 (2H, d, J = 8.8 Hz), 7.25 (2H, d, J = 8.8 Hz). FABMS (positive-ion); m/z 908 (M + Na)⁺, 884 (M – H)⁺. HRFABMS m/z (positive-ion); Calcd for C₄₉H₈₂F₃NO₉Na: 908.5839. Found: 908.5836. Anal. Calcd for C₄₉H₈₂F₃NO₉ (886.2): C, 66.41; H, 9.33; N, 1.58; F, 6.43%. Found: C, 65.19; H, 9.10; N, 1.71; F, 6.08%.

2-(4-Methoxybenzyloxy)ethyl 2-Deoxy-2-(2,2-difluorotetradecanamido)-4,6-O-isopropylidene-3-O-[(R)-3-[(Z)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (30). A solution of **29** (1.90 g, 2.14 mmol) in EtOH (10 mL) and aq 1 M NaOH (10 mL) was stirred at 60 °C for 4 h. The solution was concentrated in vacuo, diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuo to give an amine, which was dissolved in CH₂Cl₂ (15 mL). 2,2-Difluorotetradecanoic acid (681 mg, 2.57 mmol), DCC (535 mg, 2.59 mmol), and DMAP (316 mg, 2.58 mmol) were added to this solution, which was stirred for 1 h at room temperature, filtered, and concentrated in vacuo to give a mixture. The mixture was chromatographed on silica-gel column. Elution with hexane–EtOAc (4:1) gave **30** (2.13 g, 96%) as a gum. IR (CHCl₃) 3438, 2928, 2856, 1707, 1613 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (9H, t, J = 6.6 Hz), 1.26–1.32 (56H, m), 1.41 (3H, s), 1.50 (3H, s), 1.63–1.73 (2H, m), 2.01–2.11 (6H, m), 3.29–3.41 (3H, m), 3.48–3.90 (14H, m, containing 3H, s, at δ 3.81), 4.17 (1H, dt, J = 3.7, 9.5 Hz), 4.46–4.50 (2H, AB-q, J = 11.7 Hz), 4.83 (1H, d, J = 3.7 Hz), 5.31–5.38 (2H, m), 6.63 (1H, d, J = 9.5 Hz, NH), 6.88 (2H, d, J = 8.8 Hz), 7.26 (2H, d, J = 8.8 Hz). FABMS (positive-ion); m/z 1058 (M + Na)⁺. HRFABMS m/z (positive-ion); Calcd for C₆₁H₁₀₇F₂NO₉Na: 1058.7812. Found: 1058.7805. Anal. Calcd for C₆₁H₁₀₇F₂NO₉ (1036.5): C, 70.69; H, 10.41; N, 1.35; F, 3.67%. Found: C, 69.92; H, 10.18; N, 1.26; F, 3.59%.

2-Hydroxyethyl 2-Deoxy-2-(2,2-difluorotetradecanamido)-4,6-O-isopropylidene-3-O-[(R)-3-[(Z)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (31). To a solution of **30** (1.65 g, 1.59 mmol) in CH₂Cl₂ (10 mL) and H₂O (1 mL) was added DDQ (435 mg, 1.92 mmol) at room temperature. After stirring for 2 h, the reaction mixture was diluted with EtOAc, washed with sat. aq NaHCO₃ and brine, dried over MgSO₄, filtered, and concentrated in vacuo to give a crude product, which was chromatographed on a silica-gel column. Elution with hexane–EtOAc (3:1) gave **31** (1.22 g, 84%) as a gum. IR (CHCl₃) 3626, 3440, 2928, 2856, 1707 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (9H, t, J = 6.6 Hz), 1.41 (3H, s), 1.50 (3H, s), 1.26–1.54 (56H, m), 1.59–1.73

(2H, m), 1.99–2.14 (6H, m), 3.29–3.41 (3H, m), 3.49–3.65 (3H, m), 3.68–3.86 (8H, m), 4.14 (1H, dt, J = 3.7, 9.5 Hz), 4.91 (1H, d, J = 3.7 Hz), 5.31–5.39 (2H, m), 6.62 (1H, d, J = 8.8 Hz, NH). FABMS (positive-ion); m/z 938 (M + Na)⁺, 916 (M + H)⁺. HRFABMS m/z (positive-ion); Calcd for C₅₃H₉₉F₂NO₈Na: 938.7236. Found: 938.7238.

(Allyloxycarbonyl)methyl 2-Deoxy-2-(2,2-difluorotetradecanamido)-4,6-O-isopropylidene-3-O-[(R)-3-[(Z)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (32). Compound **31** (974 mg, 1.06 mmol) was treated as described in the formation of **11** from **10** to give **32** (731 mg, 71%, 3 steps) as a gum. IR (CHCl₃) 3435, 2928, 2856, 1755, 1708 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (9H, t, J = 6.6 Hz), 1.26–1.32 (56H, m), 1.40 (3H, s), 1.50 (3H, s), 1.60–1.72 (2H, m), 2.01–2.16 (6H, m), 3.28–3.41 (3H, m), 3.51–3.59 (2H, m), 3.68–3.84 (5H, m), 4.20 (2H, s), 4.21 (1H, dt, J = 3.7, 9.5 Hz), 4.64–4.66 (2H, m), 4.84 (1H, d, J = 3.7 Hz), 5.26–5.38 (4H, m), 5.90 (1H, m), 6.83 (1H, d, J = 8.8 Hz, NH). FABMS (positive-ion); m/z 992 (M + Na)⁺, 970 (M + H)⁺. HRFABMS m/z (positive-ion); Calcd for C₅₆H₁₀₁F₂NO₉Na: 992.7342. Found: 992.7349. Anal. Calcd for C₅₆H₁₀₁F₂NO₉ (970.4): C, 69.31; H, 10.49; N, 1.44; F, 3.92%. Found: C, 69.59; H, 10.50; N, 1.52; F, 3.78%.

(Allyloxycarbonyl)methyl 2-Deoxy-2-(2,2-difluorotetradecanamido)-3-O-[(R)-3-[(Z)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (33). A solution of **32** (673 mg, 0.694 mmol) in 80% AcOH aq (10 mL) was stirred at 60 °C for 3 h. The solution was diluted with EtOAc, washed with sat. aq NaHCO₃ and brine, dried over MgSO₄, filtered, concentrated in vacuo, and chromatographed on a silica-gel column. Elution with hexane–EtOAc (1:1) gave **33** (600 mg, 93%) as a white powder. IR (CHCl₃) 3605, 3431, 2928, 2856, 1754, 1707 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (9H, t, J = 6.6 Hz), 1.26–1.73 (58H, m), 2.01–2.17 (7H, m, containing OH), 3.34–3.42 (3H, m), 3.55 (1H, t, J = 8.8, 10.3 Hz), 3.62–3.68 (2H, m), 3.74–3.88 (5H, m, containing OH), 4.20 (1H, dt, J = 3.7, 9.5 Hz), 4.23 (2H, s), 4.64–4.66 (2H, m), 4.84 (1H, d, J = 3.7 Hz), 5.26–5.39 (4H, m), 5.90 (1H, m), 6.92 (1H, d, J = 9.5 Hz, NH). FABMS (positive-ion); m/z 952 (M + Na)⁺, 930 (M + H)⁺. HRFABMS m/z (positive-ion); Calcd for C₅₃H₉₇F₂NO₉Na: 952.7029. Found: 952.7070. Anal. Calcd for C₅₃H₉₇F₂NO₉ (930.3): C, 68.42; H, 10.51; N, 1.51; F, 4.08%. Found: C, 68.22; H, 10.36; N, 1.54; F, 4.29%.

(Allyloxycarbonyl)methyl 4-O-Bis(allyloxy)phosphoryl-6-O-(*t*-butyldimethylsilyl)-2-deoxy-2-(2,2-difluorotetradecanamido)-3-O-[(R)-3-[(Z)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (34). To a solution of **33** (553 mg, 0.594 mmol) in CH₂Cl₂ (10 mL) were added DMAP (96 mg, 0.784 mmol) and *t*-butyldimethylsilyl chloride (108 mg, 0.717 mmol). After stirring for 3 h at room temperature, the mixture was diluted with CH₂Cl₂, washed with sat. aq NaHCO₃ and brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo to give 6-O silylated product, which was dissolved in THF (10 mL). To this solution were added 1H-tetrazole (65 mg, 0.925 mmol) and diallyl diisopropylphosphoramidite (221 mg, 0.901 mmol). After stirring for 3 h at room temperature, 30% H₂O₂ (3 mL) was added to the reaction mixture at 0 °C. After stirring for 1 h at room temperature, the mixture was quenched with sat. aq Na₂S₂O₃, extracted with EtOAc, washed with water, sat. aq NaHCO₃ and brine, dried over MgSO₄, filtered, and concentrated in vacuo to give a crude product, which was chromatographed on a silica-gel column. Elution with hexane–EtOAc (4:1) gave **34** (600 mg, 84%) as a gum. IR (CHCl₃) 3431, 2928, 2856, 1754, 1709 cm⁻¹. ¹H NMR (500 MHz, CDCl₃) δ 0.06 (6H, s), 0.86–

0.89 (18H, m), 1.19–1.53 (56H, m), 1.67–1.79 (2H, m), 1.99–2.16 (6H, m), 3.23 (1H, m), 3.33 (2H, t, $J = 6.7$ Hz), 3.60 (1H, m), 3.69 (1H, dd, $J = 9.5$, 9.9 Hz), 3.77–3.84 (3H, m), 3.95 (1H, m), 4.18–4.24 (3H, m, containing 2H, s, at δ 4.21), 4.29 (1H, m), 4.53–4.62 (4H, m), 4.65 (2H, d, $J = 5.9$ Hz), 4.84 (1H, d, $J = 3.6$ Hz), 5.23–5.38 (8H, m), 5.86–5.97 (3H, m), 6.85 (1H, d, $J = 9.4$ Hz, NH). FABMS (positive-ion); m/z 1226 ($M + Na$)⁺, 1204 ($M + H$)⁺. HRFABMS m/z (positive-ion); Calcd for C₆₅H₁₂₀F₂NO₁₂PSiNa: 1226.8183. Found: 1226.8236. Anal. Calcd for C₆₅H₁₂₀F₂NO₁₂PSi (1204.7): C, 64.80; H, 10.04; N, 1.16; F, 3.15; P, 2.57%. Found: C, 63.96; H, 9.89; N, 1.24; F, 3.05; P, 2.44%.

(Allyloxycarbonyl)methyl 4-*O*-Bis(allyloxy)phosphoryl-2-deoxy-2-(2,2-difluorotetradecanamido)-3-*O*-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (35). Compound **34** (542 mg, 0.450 mmol) was treated as described in the formation of **14** from **13** to give **35** (448 mg, 91%) as a gum. IR (CHCl₃) 3432, 2927, 2855, 1754, 1711 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (9H, t, $J = 6.6$ Hz), 1.16–1.51 (56H, m), 1.67–1.77 (2H, m), 2.01–2.16 (6H, m), 3.22 (1H, m), 3.27–3.38 (2H, m), 3.48–3.78 (4H, m), 3.84 (1H, m), 3.96–4.12 (2H, m, containing OH), 4.19, 4.24 (2H, AB-q, $J = 16.8$ Hz), 4.25 (1H, td, $J = 3.7$, 9.5 Hz), 4.42 (1H, q, $J = 9.5$ Hz), 4.54–4.59 (2H, m), 4.63–4.67 (4H, m), 4.86 (1H, d, $J = 3.7$ Hz), 5.26–5.42 (8H, m), 5.83–5.99 (3H, m), 6.87 (1H, d, $J = 9.5$ Hz, NH). FABMS (positive-ion); m/z 1112 ($M + Na$)⁺, 1090 ($M + H$)⁺. HRFABMS m/z (positive-ion); Calcd. for C₅₉H₁₀₆F₂NO₁₂PNa: 1112.7318. Found: 1112.7338.

(Allyloxycarbonyl)methyl 4-*O*-Bis(allyloxy)phosphoryl-2-deoxy-2-(2,2-difluorotetradecanamido)-6-*O*-methyl-3-*O*-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (36). Compound **35** (304 mg, 0.279 mmol) was treated as described in the formation of **15** from **14** to give **36** (237 mg, 77%). IR (CHCl₃) 3432, 2928, 2856, 1753, 1711 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 0.88 (9H, t, $J = 6.6$ Hz), 1.25–1.51 (56H, m), 1.68–1.75 (2H, m), 1.99–2.17 (6H, m), 3.23 (1H, m), 3.33 (2H, t, $J = 6.6$ Hz), 3.40 (3H, s), 3.60 (1H, m), 3.66–3.70 (3H, m), 3.81 (1H, m), 3.89–3.93 (1H, m), 4.23 (2H, s), 4.25 (1H, td, $J = 3.7$, 9.5 Hz), 4.39 (1H, q, $J = 9.5$ Hz), 4.55–4.65 (6H, m), 4.87 (1H, d, $J = 3.7$ Hz), 5.24–5.40 (8H, m), 5.83–6.00 (3H, m), 6.84 (1H, d, $J = 9.5$ Hz, NH). FABMS (positive-ion); m/z 1126 ($M + Na$)⁺, 1104 ($M + H$)⁺. HRFABMS m/z (positive-ion); Calcd for C₆₀H₁₀₈F₂NO₁₂PNa: 1126.7475. Found: 1126.7517.

Carboxymethyl 2-Deoxy-2-(2,2-difluorotetradecanamido)-4-*O*-phosphono-3-*O*-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (37). Compound **35** (101 mg, 0.093 mmol) was treated as described in the formation of **16** from **14** to give **37** (76.5 mg, 85%) as a white powder. $[\alpha]_D^{24} + 26.5$ (c 0.7, CHCl₃). IR (KBr) 3314, 3129, 2924, 2853, 1686 cm⁻¹. ¹H NMR (500 MHz, CD₃OD) δ 0.90 (9H, t, $J = 6.8$ Hz), 1.29–1.53 (56H, m), 1.71–1.79 (2H, m), 2.03–2.15 (6H, m), 3.36–3.40 (2H, m), 3.47 (1H, m), 3.62–3.65 (3H, m), 3.78 (1H, t, $J = 9.8$ Hz), 4.00–4.08 (4H, m, containing 1H, d, $J = 15.6$ Hz, at δ 4.04), 4.13 (1H, q, $J = 9.8$ Hz), 4.22 (1H, d, $J = 15.6$ Hz), 4.82 (1H, d, $J = 3.9$ Hz), 5.31–5.38 (2H, m). FABMS (positive-ion); m/z 992 ($M + Na$)⁺, 970 ($M + H$)⁺. HRFABMS m/z (positive-ion); Calcd for C₅₀H₉₄F₂NO₁₂PNa: 992.6379. Found: 992.6381.

Carboxymethyl 2-Deoxy-2-(2,2-difluorotetradecanamido)-6-*O*-methyl-4-*O*-phosphono-3-*O*-[(*R*)-3-[(*Z*)-tetradec-7-enyloxy]tetradecyl]- α -D-glucopyranoside (38). Compound **36** (163

mg, 0.148 mmol) was treated as described in the formation of **16** from **14** to give **38** (134 mg, 92%) as a white powder. $[\alpha]_D^{24} + 44.7$ (c 0.5, CHCl₃). IR (KBr) 3314, 2925, 2853, 1758, 1685 cm⁻¹. ¹H NMR (500 MHz, CD₃OD) δ 0.90 (9H, t, $J = 6.9$ Hz), 1.29–1.54 (56H, m), 1.71–1.80 (2H, m), 1.99–2.12 (6H, m), 3.33–3.40 (5H, m, containing 3H, s, at δ 3.38), 3.45 (1H, m), 3.60 (1H, dd, $J = 5.9$, 10.8 Hz), 3.66 (1H, m), 3.75 (1H, m), 3.79–3.92 (3H, m), 4.08–4.19 (3H, m, containing 1H, d, $J = 16.6$ Hz, at δ 4.12), 4.28 (1H, d, $J = 16.6$ Hz), 4.84 (1H, d, $J = 3.5$ Hz), 5.31–5.39 (2H, m). FABMS (positive-ion); m/z 1006 ($M + Na$)⁺, 984 ($M + H$)⁺. HRFABMS m/z (positive-ion); Calcd for C₅₁H₉₆F₂NO₁₂PNa: 1006.6536. Found: 1006.6558.

Methods for Measurement of Biological Activity. The sources of the materials used in the study are as follows: lipopolysaccharide (LPS) from *E. coli* serotype 026:B6 and 12-*O*-tetradecanoylphorbol acetate (TPA) were from Sigma, St. Louis, MO; RPMI-1640 medium, fetal bovine serum (FBS), and newborn calf serum (NBCS) were from Gibco, Grand Island, NY; and human TNF α ELISA kit and mouse TNF α ELISA kit were from Genzyme, Techne, Minneapolis, MN.

Cell Culture: Human monoblastic U937 cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 100 U/mL of penicillin and 100 μ g/mL of streptomycin (growth medium).

Production of TNF α by U937 cells: U937 cells (1×10^4 /200 μ L/well) were plated in 96-well plates (Corning, Cambridge, MA), and were cultured in the presence of TPA (30 ng/mL) for 72 h at 37 °C. After removing the supernatant, the cells were incubated in 200 μ L of fresh RPMI-1640 medium containing 10% NBCS, in the absence or the presence of 30 ng/mL of LPS with graded concentrations of the compounds in the humidified atmosphere of 5% CO₂ for 4.5 h at 37 °C. After incubation, the amount of TNF α produced in the culture supernatants was determined using the TNF α ELISA kits. As a control, the amount of TNF α produced by U937 cells, which were stimulated with 30 ng/mL of LPS in the absence of compounds, was used. The concentrations (nM) of the compounds required to inhibit the LPS-induced TNF α production by U937 cells by 50% (IC₅₀) was calculated from the control amount. All experiments were carried out at least twice, showing that the data are reproducible.

Production of TNF α by mouse peritoneal macrophage: C57BL/6 female mice (6–7 wk old) were obtained from Charles River Japan, Inc., Yokohama, Japan. Peritoneal resident macrophages were collected by peritoneal lavage with ice-cold saline. After washing, cells were resuspended in RPMI-1640 medium supplemented with 10% NBCS, 100 U/mL of penicillin and 100 μ g/mL of streptomycin, and were plated in 96-well plates (5×10^4 /100 μ L/well). After incubation overnight at 37 °C, nonadherent cells were removed by washing three times with RPMI-1640 medium containing 10% NBCS, and adherent cells were incubated in 100 μ L of the same medium, in the absence or presence of 10 ng/mL of LPS with graded concentrations of the compounds in the humidified atmosphere of 5% CO₂ for 4.5 h at 37 °C. After incubation, the amount of TNF α produced in the culture supernatants was determined using the mouse TNF α ELISA kits. IC₅₀ of the compounds was calculated as described above.

We thank Ms. Mariko Takai (Institute of Science and Technology, Inc.) for measurement of biological activity of mouse PEC-macrophage cells.

References

- 1 a) M. Imoto, H. Yoshimura, N. Sakaguchi, S. Kusumoto, and T. Shiba, *Tetrahedron Lett.*, **26**, 1545 (1985). b) M. Imoto, H. Yoshimura, T. Shimamoto, N. Sakaguchi, S. Kusumoto, and T. Shiba, *Bull. Chem. Soc. Jpn.*, **60**, 2205 (1987). c) Cf. T. Takahashi, Nakamoto, K. Ikeda, and K. Achiwa, *Tetrahedron Lett.*, **27**, 1819 (1986).
- 2 "Endotoxin in Health and Diseases," ed by H. Brade, S. M. Opal, S. N. Vogel, and D. C. Morrison, Marcel Dekker Inc., New York, Basel (1999).
- 3 C. Galanos, O. Luderitz, E. T. Rietschel, and O. Westphal, *Int. Rev. Biochem.*, **14**, 293 (1977).
- 4 a) N. Qureshi, J. P. Honovich, H. Hara, R. J. Cotter, and K. Takayama, *J. Biol. Chem.*, **263**, 5502 (1988). b) N. Qureshi, K. Takayama, and R. Kurtz, *Infec. Immunol.*, **51**, 441 (1991). c) N. Qureshi, K. Takayama, K. C. Meyer, T. N. Kirkland, C. A. Bush, L. Chen, R. Wang, and R. J. Cotter, *J. Biol. Chem.*, **266**, 6532 (1991). d) W. J. Christ, P. D. McGuinness, O. Asano, Y. Wang, M. A. Mullarkey, M. Perez, L. D. Hawkins, T. A. Blythe, G. R. Dubuc, and A. L. Robidoux, *J. Am. Chem. Soc.*, **116**, 3637 (1994). e) I. A. Kaltashov, V. Doroshenco, R. J. Cotter, K. Takayama, and N. Qureshi, *Anal. Chem.*, **69**, 2317 (1997).
- 5 W. J. Christ, D. P. Rossignol, S. Kobayashi, and T. Kawata, US Patent 5935938 (Aug. 10, 1999).
- 6 M. Matsuura, Y. Kojima, J. Y. Homma, Y. Kubota, A. Yamamoto, M. Kiso, H. Ishida, and A. Hasagawa, *FEBS Lett.*, **167**, 226 (1984).
- 7 M. Shiozaki, N. Deguchi, W. M. Macindoe, M. Arai, H. Miyazaki, T. Mochizuki, T. Tatsuta, J. Ogawa, H. Maeda, and S. Kurakata, *Carbohydr. Res.*, **283**, 27 (1996).
- 8 D. P. Rossignol, L. D. Hawkins, W. J. Christ, K. Kobayashi, T. Kawata, M. Lynn, I. Yamatsu, and Y. Kishi, Chapter 47 in "Endotoxin in Health and Diseases," ed by H. Brade, S. M. Opal, S. N. Vogel, and D. C. Morrison, Marcel Dekker, Inc., New York, Basel (1999).
- 9 M. Subchev, A. Harizanov, W. Francke, S. Franke, E. Plass, A. Reckziegel, F. Schröder, J. A. Pickett, L. J. Wadhams, and C. M. Woodcock, *J. Chem. Ecol.*, **24**, 1141 (1998).
- 10 a) R. Rossi, A. Carpita, L. Gaudenzi, and M. G. Quirici, *Gass. Chim. Ital.*, **110**, 237 (1980). b) O. P. Vig, M. L. Sharma, A. Sabharwal, and N. Vohra, *Indian J. Chem. Sect B*, **25**, 1042 (1986). c) J. S. McElfresh, J. G. Miller, and D. Rubinoff, *J. Chem. Ecol.*, **27**, 791 (2001).
- 11 Y. Watanabe, K. Miura, M. Shiozaki, S. Kanai, S. Kurakata, and M. Nishijima, *Carbohydr. Res.*, **332**, 257 (2001).
- 12 Y. Watanabe, T. Mochizuki, M. Shiozaki, S. Kanai, S. Kurakata, and M. Nishijima, *Carbohydr. Res.*, **333**, 203 (2001).
- 13 W.-C. Liu, M. Oikawa, K. Fukase, Y. Suda, and S. Kusumoto, *Bull. Chem. Soc. Jpn.*, **72**, 1377 (1999).
- 14 D. B. Press and J. C. Dess, *J. Org. Chem.*, **48**, 4155 (1983).
- 15 Y. Hayakawa, H. Kato, T. Nobori, R. Noyori, and J. Imai, *Nucl. Acids Symp. Ser.*, **17**, 97 (1986).
- 16 M. Shiozaki, Y. Kobayashi, N. Ishida, M. Arai, T. Hiraoka, M. Nishijima, S. Kuge, T. Otsuka, and Y. Akamatsu, *Carbohydr. Res.*, **222**, 57 (1991).
- 17 D. T. Golenbock, R. Y. Hampton, N. Qureshi, K. Takayama, and C. R. Raetz, *J. Biol. Chem.*, **266**, 19490 (1991).